Urgent reversal of warfarin with prothrombin complex concentrate: Where are the evidence-based data?

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 5, 2006, Pages 963-966

  Kessler, Craig M ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9 COMPLEX; FRESH FROZEN PLASMA; PROPLEX T; PROTEIN C; PROTEIN S; PROTHROMBIN COMPLEX; PROTHROMBINEX T; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN SURGERY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; LUNG INJURY; MEDICAL RECORD REVIEW; NOTE; PLASMA TRANSFUSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK BENEFIT ANALYSIS; RISK FACTOR; THROMBOEMBOLISM; THROMBOGENICITY; THROMBOSIS;

ANTICOAGULANTS; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; PROTHROMBIN; WARFARIN;

EID: 33645648065     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01944.x     Document Type: Note

References (24)

1. Plohoros T, Schoenborn J, Elicker J, Davis B. Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months Of 2005 and Announces EPS Guidance for 2006. Press Release. Princeton, NJ: Bristol-Myers Squibb Company, January 25, 2006.
2. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment. An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
3. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-65.
4. Campbell P, Roberts G, Eaton V. Managing warfarin therapy in the community. Aust Prescriber 2001; 24: 86-9.
5. van der Meer FJM, Rosendaal FR, Vanderbroucke JP. Bleeding complications in oral anticoagulant therapy: An analysis of risk factors. Arch Intern Med 1993; 153: 1557-62.
6. Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Büller HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLOS Med 2005; 2: 0e312.
7. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996; 124: 970-9.
8. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-28.
9. Agency for Health Care Policy and Research. Life-saving treatments to prevent stroke underused. Press release, September 1995 [WWW document]. Available at URL http://www.ahcpr.gov/news/press/stroke.htm (accessed on 31 March 2006).
10. Lankiewicz MW, Hays J, Friedman K, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4: 967-70.
11. Duguid J, O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM. Guidelines for the use of fresh frozen plasma, cryoprecipitate and cryosupernatant. British Committee for Standards in Haematology Blood Transfusion task force. Br J Haematol 2004; 126: 11-28.
12. Ansel J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E, The pharmacology and management of vitamin K antagonists. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 204S-33S.
13. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood E. Warfarin reversal: Consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 494-7.
14. Conway EM, Bauer KA, Barzegar S, Rosenberg RD. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest 1987; 80: 1535-44.
15. Xi M, Beguin S, Hemker HC. The relative importance of the factors II, VII, IX, and X for the prothrombinase activity in plasma of orally anticoagulated patients. Thromb Haemost 1989; 62: 788-91.
16. Sarode R, Rawal A, Lee R, Shen YM, Frenkel EP. Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy. Br J Haematol 2006; 132: 604-9.
17. Hemphill JC. Treating warfarin-related intracerebral hemorrhage. Stroke 2006; 37: 6-11.
18. Sjöblom L, Hårdemark H, Lindgren A, Norrving B, Fahlén M, Samuelsson M, Stigendal L, Stockelberg D, Taghavi A, Wallrup L, Wallvik J. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy. Stroke 2001; 32: 2567-74.
19. Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1881; 28: 3-5.
20. Deveras RE, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 137: 884-8.
21. Roberts HR. Recombinant factor VIIa: A general hemostatic agent? Yes. J Thromb Haemost 2004; 2: 1691-4.
22. Freeman WD, Brott TG, Barrett KM, Castillo PR, Deen HG, Czervionke LF, Meschia JF. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004; 79: 1495-500.
23. Brody DL. Aiyagari V, Shackleford AM. Diringer MN. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005; 2: 263-7.
24. O'Connell KA. Wood JJ. Wise RP. Lozier JN. Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-8.